Inhaled cannabis was more effective than inhaled placebo in interference in mood, but there was no statistically significant difference in pain rating between cannabis and placebo in adults with Sickle Cell Disease (SDC) and chronic pain.
Why this matters
SCD is characterized by chronic pain, often requiring high doses of opioids for prolonged periods. A synthetic cannabinoid has previously been shown to attenuate both chronic and acute hyperalgesia in humanized mouse models, but the effect of cannabis on chronic pain in adult humans with SDC is unknown.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.